Organization
OBI Pharma
7 clinical trials
Clinical trial
A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.Status: Terminated, Estimated PCD: 2022-04-07
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-10-27
Clinical trial
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-02-13
Clinical trial
A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer SubjectsStatus: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-06-01